Log in to save to my catalogue

Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metas...

Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metas...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6726691

Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer

About this item

Full title

Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer

Publisher

England: John Wiley & Sons, Inc

Journal title

Cancer science, 2019-09, Vol.110 (9), p.2875-2883

Language

English

Formats

Publication information

Publisher

England: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Previous studies have shown sex‐related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown. We examined sex‐related differences in the safety of S‐1 plus oxaliplatin (SOX) and S‐1 plus cisplatin (CS) in 663 metastatic gastric cancer patients taking part in a...

Alternative Titles

Full title

Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6726691

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6726691

Other Identifiers

ISSN

1347-9032

E-ISSN

1349-7006

DOI

10.1111/cas.14117

How to access this item